Shares of PDL BioPharma (NASDAQ:PDLI) saw a significant decrease in short interest during the month of January. As of March 14th, there was short interest totalling 26,774,601 shares, a decrease of 6.8% from the February 28th total of 28,728,945 shares, AnalystRatingsNetwork.com reports. Currently, 20.9% of the company’s stock are sold short. Based on an average trading volume of 3,618,174 shares, the short-interest ratio is presently 7.4 days. PDL BioPharma Inc (NASDAQ:PDLI), shares after opening at $8.01 moved to $8.24 on last trade day and at the end of the day closed at $8.20. Company price to sales ratio in past twelve months was calculated as 2.97 and price to cash ratio as 13.21. PDL BioPharma Inc (NASDAQ:PDLI), showed a negative weekly performance of 1.32%.
Vodafone Group Plc (ADR) (NASDAQ:VOD) stock had its “overweight” rating restated by equities research analysts at JPMorgan Chase & Co. in a research note issued to investors on Tuesday, Analyst Ratings.Netreports. They currently have a GBX 270 ($4.48) price objective on the stock. JPMorgan Chase & Co.’s target price would suggest a potential upside of 24.08% from the stock’s previous close. Vodafone Group Plc (ADR) (NASDAQ:VOD), shares advanced 0.25% in last trading session and ended the day on $36.04. Vodafone Group Plc (ADR) (NASDAQ:VOD), return on equity ratio is recorded as 24.80% and its return on assets is 13.50%. Vodafone Group Plc (ADR) (NASDAQ:VOD), yearly performance is 32.21%.
On April 7, 2014, Flotek Industries Inc (NYSE:FTK) announced it has entered into an Agreement to acquire certain intellectual property that will expand Flotek’s use of its patented Complex nano-Fluid™ technology into drilling fluids systems, providing a superior solution for a myriad of challenges, especially those presented by unconventional drilling programs. Flotek Industries Inc (NYSE:FTK), shares moved down 2.03% in last trading session and was closed at $26.98, while trading in range of $ 26.44 – 27.98. Flotek Industries Inc (NYSE:FTK), year to date (YTD) performance is 0.32%.
On April 4, 2014, Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics, announced the appointment of Darlene Deptula-Hicks to its Board of Directors. Xenetic Biosciences Inc (OTCBB:XBIO). On last trading day company shares ended up $0.960.
Leave a Reply